Form 4: ANAPTYSBIO Director Granted Equity Compensation

ANAPTYSBIO, INC. director John P. Schmid received grants of 5,500 stock options and 4,000 restricted stock units as part of his compensation.

Summary

• Director John P. Schmid was granted 5,500 stock options and 4,000 Restricted Stock Units (RSUs) on January 6, 2026.
• The stock options have an exercise price of $43.91 and are set to expire on January 5, 2036.
• The stock options will vest monthly at a rate of 1/12 of the total shares, commencing February 6, 2026, contingent on continued service to the Issuer.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
• The RSUs will vest 100% on the date of the Issuer's 2027 annual meeting of shareholders, contingent on continued service to the Issuer.
• Following these transactions, John P. Schmid directly beneficially owns 5,500 stock options and 4,000 RSUs.

Sentiment

Score: 6

Explanation: Slightly positive as it represents routine director compensation, aligning interests with shareholders, but does not indicate any new operational or financial performance.

Positives

• Director John P. Schmid received 5,500 stock options, aligning his interests with shareholder value creation.
• The grant of 4,000 Restricted Stock Units (RSUs) provides a future equity stake for the director, contingent on continued service.
• Equity compensation is a common method to incentivize long-term commitment and performance from directors.

Negatives

• The issuance of new equity awards could lead to minor future dilution for existing shareholders upon vesting and exercise.

Risks

• The vesting of both stock options and RSUs is contingent on John P. Schmid's continued provision of service to ANAPTYSBIO, INC.
• The value of the stock options is dependent on the future market price of ANAPTYSBIO's common stock exceeding the exercise price of $43.91.

Future Outlook

The filing does not provide a future outlook for the company, but details future vesting schedules for the granted equity awards.

Industry Context

Equity compensation, including stock options and restricted stock units, is a standard practice across the biotechnology and pharmaceutical industries for incentivizing directors and executives. This aligns the interests of leadership with long-term shareholder value, a common trend in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a director is a common form of compensation in publicly traded companies, particularly within the biotechnology sector.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar equity-based incentives to attract and retain talent and align director interests with long-term company performance.
• The specific number of units and vesting schedules are typically determined by compensation committees based on company size, performance, and peer group benchmarks, though this filing does not provide those comparative details.

Corporate Governance

Related Party Transactions

• The grant of 5,500 stock options and 4,000 Restricted Stock Units to John P. Schmid, a director of ANAPTYSBIO, INC., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon exercise of options and settlement of RSUs, but improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned for general employees.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Monthly vesting of 1/12 of the stock options commencing February 6, 2026.
• 100% vesting of the Restricted Stock Units on the date of the Issuer's 2027 annual meeting of shareholders.
• Potential exercise of stock options by John P. Schmid if the stock price exceeds $43.91 before January 5, 2036.
• Settlement of RSUs into common stock upon vesting.

Key Dates

Keywords

ANAPTYSBIO, ANAB, Form 4, insider transaction, stock option, restricted stock unit, equity compensation, director compensation, vesting, corporate governance